Stylianos Tsagarakis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8119306/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Testosterone, free, bioavailable and total, in patients with COVID-19. Minerva Endocrinology, 2022, 47, .	0.6	5
2	Cardiometabolic Disease Burden and Steroid Excretion in Benign Adrenal Tumors. Annals of Internal Medicine, 2022, 175, 325-334.	2.0	53
3	Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study. Lancet Diabetes and Endocrinology,the, 2022, 10, 499-508.	5.5	55
4	MO622: Clinical Value of Kidney Biopsy in Patients with Diabetes Mellitus and Nephrotic - Range Proteinuria: Correlation of Clinical and Laboratory Findings with Histopathological Data. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0
5	Cushing's disease: risk of recurrence following trans-sphenoidal surgery, timing and methods for evaluation. Pituitary, 2022, 25, 718-721.	1.6	6
6	Current approach of primary bilateral adrenal hyperplasia. Current Opinion in Endocrinology, Diabetes and Obesity, 2022, 29, 243-252.	1.2	2
7	Progression of Albuminuria Among Patients with Type 1 Diabetes Mellitus: A Long Term Observational Follow-up Study. Experimental and Clinical Endocrinology and Diabetes, 2021, 129, 276-282.	0.6	0
8	Histology is more ιmportant than persistent anti‶g antibodies for progression of differentiated thyroid cancer. Clinical Endocrinology, 2021, 95, 217-223.	1.2	1
9	Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome (LOGICS): Results From a Double-Blind, Placebo-Controlled, Randomized Withdrawal Study. Journal of the Endocrine Society, 2021, 5, A526-A526.	0.1	4
10	Increased Glucocorticoid Receptor Alpha Expression and Signaling in Critically Ill Coronavirus Disease 2019 Patients*. Critical Care Medicine, 2021, 49, 2131-2136.	0.4	10
11	Thyroid hormone alterations in critically and non-critically ill patients with SARS-CoV-2 infection. Endocrine Connections, 2021, 10, 646-655.	0.8	19
12	Glycemia, Beta-Cell Function and Sensitivity to Insulin in Mildly to Critically Ill Covid-19 Patients. Medicina (Lithuania), 2021, 57, 68.	0.8	29
13	Consensus on diagnosis and management of Cushing's disease: a guideline update. Lancet Diabetes and Endocrinology,the, 2021, 9, 847-875.	5.5	315
14	Pituitary–Adrenal Responses and Glucocorticoid Receptor Expression in Critically Ill Patients with COVID-19. International Journal of Molecular Sciences, 2021, 22, 11473.	1.8	8
15	Loss of KDM1A in GIP-dependent primary bilateral macronodular adrenal hyperplasia with Cushing's syndrome: a multicentre, retrospective, cohort study. Lancet Diabetes and Endocrinology,the, 2021, 9, 813-824.	5.5	34
16	A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e937-e946.	1.8	207
17	Longitudinal evaluation of glucocorticoid receptor alpha/beta expression and signalling, adrenocortical function and cytokines in critically ill steroid-free patients. Molecular and Cellular Endocrinology, 2020, 501, 110656.	1.6	13
18	Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study. Lancet Diabetes and Endocrinology,the, 2020, 8, 773-781.	5.5	129

STYLIANOS TSAGARAKIS

#	Article	IF	CITATIONS
19	Pituitary dysfunction after traumatic brain injury: prevalence and screening strategies. Expert Review of Endocrinology and Metabolism, 2020, 15, 341-354.	1.2	8
20	Approach to patients with bilateral adrenal incidentalomas. Current Opinion in Endocrinology, Diabetes and Obesity, 2020, 27, 125-131.	1.2	6
21	Long-term outcome of differentiated thyroid cancer in children and young adults: risk stratification by ATA criteria and assessment of pre-ablation stimulated thyroglobulin as predictors of disease persistence. Endocrine, 2020, 70, 566-574.	1.1	17
22	Suprasellar extension independently predicts preoperative pituitary hormone deficiencies in patients with nonfunctioning pituitary macroadenomas: a single-center experience. Hormones, 2020, 19, 245-251.	0.9	4
23	OR25-05 Increased Overall Mortality and Cardiovascular Morbidity in Patients with Adrenal Incidentalomas and Autonomous Cortisol Secretion: Results of the ENS@T NAPACA-Outcome Study. Journal of the Endocrine Society, 2020, 4, .	0.1	0
24	Decreased glucocorticoid receptor expression during critical illness. European Journal of Clinical Investigation, 2019, 49, e13073.	1.7	17
25	Metformin and gut microbiota: their interactions and their impact on diabetes. Hormones, 2019, 18, 141-144.	0.9	83
26	Traumatic brain injury induced neuroendocrine changes: acute hormonal changes of anterior pituitary function. Pituitary, 2019, 22, 283-295.	1.6	18
27	Adrenal Imaging in Patients with Endocrine Hypertension. Endocrinology and Metabolism Clinics of North America, 2019, 48, 667-680.	1.2	6
28	Medical therapy for non-functioning pituitary tumors—a critical approach. Hormones, 2019, 18, 117-126.	0.9	6
29	Autoimmune thyroiditis in patients with type 1 diabetes mellitus: AÂlong-term follow-up study. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2019, 13, 608-611.	1.8	9
30	Diagnosis and management of primary bilateral macronodular adrenal hyperplasia. Endocrine-Related Cancer, 2019, 26, R567-R581.	1.6	50
31	DIAGNOSIS OF ENDOCRINE DISEASE: The role of the desmopressin test in the diagnosis and follow-up of Cushing's syndrome. European Journal of Endocrinology, 2018, 178, R201-R214.	1.9	50
32	Microbiome and diabetes: Where are we now?. Diabetes Research and Clinical Practice, 2018, 146, 111-118.	1.1	93
33	Increased glucocorticoid receptor expression in sepsis is related to heat shock proteins, cytokines, and cortisol and is associated with increased mortality. Intensive Care Medicine Experimental, 2017, 5, 10.	0.9	48
34	Therapeutic trends and outcome of acromegaly: a single center experience over a 40-year period. Hormones, 2016, 15, 368-376.	0.9	4
35	Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. European Journal of Endocrinology, 2016, 175, G1-G34.	1.9	1,173
36	Do patients with incidentally discovered bilateral adrenal nodules represent an early form of ARMC5-mediated bilateral macronodular hyperplasia?. Endocrine, 2016, 53, 801-808.	1.1	20

STYLIANOS TSAGARAKIS

#	Article	IF	CITATIONS
37	No considerable changes in papillary thyroid microcarcinoma characteristics over a 30-year time period. BMC Research Notes, 2016, 9, 252.	0.6	14
38	Evidence of Subcutaneous Tissue Lipolysis Enhancement by Endogenous Cortisol in Critically Ill Patients Without Shock. In Vivo, 2015, 29, 497-9.	0.6	1
39	X-linked adrenoleukodystrophy: are signs of hypogonadism always due to testicular failure?. Hormones, 2014, 13, 146-152.	0.9	8
40	Impact of early <i>vs</i> late postoperative radioiodine remnant ablation on final outcome in patients with lowâ€risk wellâ€differentiated thyroid cancer. Clinical Endocrinology, 2014, 80, 459-463.	1.2	28
41	Adrenocorticotropic Hormone Independent Macronodular Adrenal Hyperplasia due to Aberrant Receptor Expression: Is Medical Treatment Always an Option?. Endocrine Practice, 2013, 19, e77-e82.	1.1	17
42	Subclinical hypercortisolism: debatable or visible on the lightbox?. Endocrine, 2012, 42, 7-8.	1.1	5
43	Endocrine incidentalomas—challenges imposed by incidentally discovered lesions. Nature Reviews Endocrinology, 2011, 7, 668-680.	4.3	32
44	High prevalence of subclinical hypercortisolism in patients with bilateral adrenal incidentalomas: a challenge to management. Clinical Endocrinology, 2011, 74, 438-444.	1.2	47
45	Aberrant cortisol responses to physiological stimuli in patients presenting with bilateral adrenal incidentalomas. Endocrine, 2011, 40, 437-444.	1.1	25
46	Lymphocytic Hypophysitis: Late Recurrence Following Successful Transsphenoidal Surgery. Endocrine, 2004, 25, 085-090.	2.2	12
47	Relationship of thyroid function to post-traumatic S-100b serum levels in survivors of severe head injury: preliminary results. Intensive Care Medicine, 2004, 30, 298-301.	3.9	11
48	Endocrine abnormalities in critical care patients with moderate-to-severe head trauma: incidence, pattern and predisposing factors. Intensive Care Medicine, 2004, 30, 1051-1057.	3.9	83
49	The low-dose corticotropin stimulation test in acute traumatic and non-traumatic brain injury: incidence of hypo-responsiveness and relationship to outcome. Intensive Care Medicine, 2004, 30, 1216-1219.	3.9	44
50	Assessment of GH reserve before and after successful treatment of adult patients with Cushing's syndrome. Clinical Endocrinology, 2004, 60, 309-314.	1.2	31
51	Hypothalamic-pituitary-adrenal axis dysfunction in critically ill patients with traumatic brain injury: Incidence, pathophysiology, and relationship to vasopressor dependence and peripheral interleukin-6 levels*. Critical Care Medicine, 2004, 32, 404-408.	0.4	150